2nd Annual Summit on ^{Cell Therapy, Tissue Science and Regenerative Medicine} November 9-10, 2018 Atlanta, Georgia, USA

Through his dual roles as Vice President for University Partnerships at the Maryland Technology Development Corporation (TEDCO) and Executive Director of the Maryland Stem Cell Research Fund, Dr. Gincel oversees programs on university research, tech transfer, and commercialization and innovation that contribute to economic growth in Maryland. He is dedicated to increasing research capacity for Maryland scientists, supporting cutting-edge technology development, and ultimately, developing cures for debilitating diseases. Recently Dr. Gincel launched a new initiative called Accelerating Cures to support regenerative medicine and cell therapy technologies moving from research to commercialization and finally to clinical trials. Accelerating Cure has five programs to address the different stages the cell therapy technologies to go through. Dr. Gincel received his Bachelor of Science and Doctor of Philosophy (Biochemistry and Neuroscience) from the Ben-Gurion University (Israel).

Accelerating Cures to support regenerative medicine and cell therapy technologies

Martin D’Souza has obtained his PhD degree from the University of Pittsburgh, PA, USA. He is a Professor and Director of Graduate Programs in the College of Pharmacy at Mercer University in Atlanta, Georgia. He also serves as the Director of the Clinical Laboratory and Co-Director of the Center for Drug Delivery Research. He has graduated over 50 PhD students and has published over 100 manuscripts. He has been the recipient of several research grants from the National Institutes of Health (NIH), the American Diabetes Association, the Georgia Cancer Coalition, and Georgia Research Alliance. He serves on several Editorial Boards and is a journal reviewer for over 10 scientific journals and has several patents issued in the area of Nanotechnology.

Tissue bio-engineering- applications, transplantation of pancreatic cells in diabetes, design of novel patented technologies to deliver nano vaccines via the oral, buccal, parenteral and microneedle based transdermal route

Dr. Williams is a DVM with over 35 years’ experience performing translational research using different animal models of human disease. He has published over 120 full length manuscripts and 20 chapters and reviews. His focus is on women’s health and recently on regenerative medicine approaches to restoration of the urinary sphincter for women with urinary incontinence. This presentation is a review of determinates of cell therapy efficacy on urinary incontinence using nonhuman primates as an animal model of aging, chronicity of disease, estrogen deficiency, and obesity. The presentation concludes with a discussion of regenerative pharmacologic approaches for these different populations.

Estrogen Replacement Therapy, Apolipoproteins E, Estradiol, Estrogens, Atherosclerosis

Jonathan Schwartz has over 30 years doing international business consulting for emerging medical technologies and has been focused on stem cell technologies and regenerative medicine for the past six years. He currently is the Managing Director of the Regenerative Cellular Institute in the United States and does business consulting for several companies globally, including, Mystem, Bioquark, WinCell, StemCells21, IntellihealthPlus, Al Mediq, Glo PRP, WeHealPlus, and Arpwave. He has previously worked in many capacities with Spacelabs Medical, GE Healthcare, Intellicell Biosciences, Coloplast, and Smith and Nephew. He has degrees from Queens College, Almeda University and NYU Medical School.

INTERNATIONAL CONSULTING AND GLOBAL BUSINESS DEVELOPMENT FOR CELLULAR THERAPIES AND REGENERATIVE MEDICINE TECHNOLOGIES

I have worked in the area of heme oxygenase (HO) research for over 3 decades focusing on the pathophysiology of the HO system in hypertension, diabetes and, most recently, the metabolic syndrome. I am presently studying the molecular mechanisms governing the interplay between lipid autacoids, adiponectin and the HO system in the regulation of adipocyte function in obesity induced-hypertension. I have extensive experience in experimental approaches of gene and stem cell therapy. My experience in stem cell biology goes back to my discovery in 1982 of the role of HO in bone marrow stem cell and stromal cell (mesenchymal stem cells) function. My record of success and productivity in the area of HO in hypertension and cardiovascular disease goes back to the first paper published on this topic in Science (1989). Mentoring is a critical element of this proposal and I bring considerable mentoring experience. I have successfully mentored undergraduate, graduate, post-doctoral and clinical fellows and junior faculty for more than 35 years. Many of these individuals have attained positions of leadership including departmental chairs, full professorships, chiefs of clinical departments and have achieved national and international recognition in their respective fields. As former chair of Physiology and Pharmacology at the University of Toledo, I was able to mentor junior and mid-level faculty and increased their success rate when applying for NIH funding. I have the necessary experience and expertise to insure the success of this COBRE application, which is designed to address the high incidence of obesity and metabolic syndrome in Appalachia populations.

Cellular and molecular mechanisms of HO-1 cytoprotective actions and developing therapeutic strategies for treatment of cardiovascular and metabolic diseases

Hazem Barmada is a Cardiovascular and Thoracic Surgeon. He was graduated from St. Andrews and Manchester Universities in 1971 and 1974, respectively. He was active in martial arts in Britain from 1968 to 1984 and was a Medical Officer to the Martial Arts Commission and other major karate organizations in GB from 1974 to 1984. He is a Fellow of the Royal College of Surgeons of Edinburgh in General and Cardiothoracic Surgery, the intercollegiate British Boards in Cardiothoracic Surgery and the Royal Society of Medicine in London and is also a Member of the Society of Thoracic Surgeons and American College of Phlebology. He has two patents and published a number of papers. His interests include regenerative medicine and stem cell research, sports injuries and venous and lymphatic disease.

Regenerative and stem cell medicine

Dr. Bill Tawil obtained his Bachelor degree in Biochemistry from the University of California at Berkeley. He then completed his Master and Doctorate degrees in Neuroscience at McGill University in Montreal studying the expression and function of adhesion cell surface receptors (integrins) in the Central Nervous System and during tumor metastasis. Subsequently, he spent four years of postdoctoral training at the Center for Cancer Research at MIT under the supervision of Dr. Richard Hynes investigating cell adhesion during the cell cycle. As a Scientist and a Senior Scientist at U.S. Surgical Corporation and at Baxter BioSurgery, he worked in the field of Tissue Regeneration examining products (synthetic and biologics) that successfully deliver bioactive substances and cells to enhance healing in soft and hard tissue defects. He, then, acted as a director of global expansion at Baxter BioSurgery responsible for scientific initiatives related to tissue engineering establishing collaborations between Baxter and other companies and academic institutions. Presently, Bill is a Director of R&D at CR Bard. Bill is also an adjunct professor in the Bioengineering Department at UCLA where he is continuing his research in Tissue Engineering, specifically on 3D constructs. He is on council for the Tissue Engineering and Regenerative Medicine (TERMIS) – North America society and on the Executive Editorial Board for the Tissue Engineering Journal. Bill was the co – Chair for TERMIS 2008 meeting and the Co – Chair for 2016 meeting. He has been the treasurer for TERMIS since 2009. Bill served on the BOD for the Wound Healing Society (WHS) from 2000 to 2005 and he was the treasurer from 2002 to 2005. He was on the Program Committee for the WHS from 1998 – 2000 and again from 2005 – 2008 including the co – chair for the 2007 meeting. Bill believes strongly that the interaction between academia and industry is an expedient and successful way to get products to the patients.

Use of biomaterials to deliver cells such as fibroblasts, keratinocytes, and stem cells

Dr. Basmaji, is a Brazilian physicist, inventor of artificial natural extracellular matrix for the manufacture of three-dimensional advanced wound management, Tissue engineering, Regenerative medicine, stem cell, Bionanotechnology, Drug deliveryand artificial cartilage grafts.Dr.Basmaji has also experience on Engineering and Bionanotechnology, Drug delivery processing for Health applications, and other process industries worldwide.

Cell Biology, Molecular Biology, Immunology

Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doctors. In 1980, graduated from Astrakhan State Med University with MD. In 1985, maintained his PhD at I.M. Sechenov Moscow Medical Academy. In 2001, maintained his Doctor Degree at the National Inst of Immunology. From 1985 through 1987, worked as a Post Doc Research Associate, Inst of Med Enzymology, USSR Academy of Medical Sciences. From 1987 through 1989, was a Senior Res Associate, Koltzov Inst of Developmental Biology, USSR Academy of Sciences. From 1989 through 1995, was being a Head of the Lab of Clin Immunology and Immunobiotechnology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, was being a Chairman of the Dept for Clin Immunology, Moscow Clinical Research Institute (MONIKI). In 1993-1996, was an Executice Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, Dr Sergey Suchkov is: Chair, Dept for Translational Medicine, Moscow Engineering Physical Institute (MEPhI), and Director, Center for Personalized Medicine, Sechenov University, Russia

Translational Medicine

Dr. Wolfgang Knirsch is a member of the board of Vita 34 AG since June 2016 and was appointed as CEO of Vita 34 AG in June 2017. After he received his PhD in inorganic chemistry by RWTH Aachen he hold leading positions in the field of Marketing & Sales at Hoechst AG, Merk KGaA and Biotest AG. In his position as Vice President of International Business at Biotest AG, he successfully advanced the strategically relevant department worth several hundred millions of Euros involving distribution partners worldwide.

Stem cell bank

Yufang Shi is a Professor and the Director of the Institute of Health Sciences, Shanghai Institutes for Biological Sciences of Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine. He is also a University Professor of the Child Health Institute of New Jersey at Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey. He received a veterinary degree from Shandong Agricultural University, China. His M.Sc. in immunoparasitology and Ph.D. in Immunology were from University of Alberta. His postdoctoral training was at the University of Toronto. From 1995 to 2001, he was an Assistant Professor and Associate Professor at the Holland Laboratory of American Red Cross and George Washington University. He move to Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey in 2001 and was promoted to a Full Professor with a University Professor title in 2003. Since 1988, Dr. Shi has been studying apoptosis, especially in T cells. He published more than 130 papers on activation-induced cell death (AICD), role of c-myc in apoptosis, T cell immunobiology, and mesenchymal stem cell immunology in Nature, Science, Nature Medicine, Cell Stem Cell, Immunity, J. Exp. Med and other journals. Dr. Shi is a Receiving Editor of Oncogene and an Editor of Cell Death and Diseases. He was an Associate Editor of the Journal of Immunology, an Editor of Cell Research and is currently on the editorial boards of Journal of Biological Chemistry, Cellular and Molecular Immunology, Journal of Molecular Cell Biology, and American Journal of Translational Research.

Mesenchymal stem cells, Tumor stroma and tumor immunology, Molecular mechanisms of activation-induced cell death in T cell subpopulations

Dr. Yaegaki had received Doctor of Dental Science, and then completed his PhD in Medicine from Kureme University Medical Biochemistry and postdoctoral studies from University of British Columbia. He was trained as an Oral maxillofacial Surgeon at School of Medicine Kurume University. His speciallity was facial injuaries. He is the director and head of Oral Health at Nippon Dental University, which is the oldest dental school in Asia, also a Dean of PhD program. He has published more than 100 papers and 20 books.

Transplantations, Cirrhosis, Dental Science